These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Rofecoxib and the risk of adverse upper gastrointestinal effects. Whitney E JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789660 [No Abstract] [Full Text] [Related]
3. Upper gastrointestinal toxicity of rofecoxib and naproxen. Gupta S N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336057 [No Abstract] [Full Text] [Related]
4. Rofecoxib and the risk of adverse upper gastrointestinal effects. Freston J JAMA; 2000 Apr; 283(15):1960; author reply 1961. PubMed ID: 10789659 [No Abstract] [Full Text] [Related]
5. Rofecoxib-associated upper gastrointestinal bleed: a case report. Freedman GM; Kreitzer JM; Badola R Mt Sinai J Med; 2002; 69(1-2):105-6. PubMed ID: 11832981 [TBL] [Abstract][Full Text] [Related]
6. Upper gastrointestinal toxicity of rofecoxib and naproxen. Delgado Fernández M; Zambrana García JL; Diez García F N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336056 [No Abstract] [Full Text] [Related]
7. Celecoxib and rofecoxib. Brinker AD; Bonnel RA; Feight AG; Nourjah P J Am Dent Assoc; 2001 Nov; 132(11):1502, 1504. PubMed ID: 11806062 [No Abstract] [Full Text] [Related]
8. Tolerability of rofecoxib versus naproxen. Rusche JM Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197028 [No Abstract] [Full Text] [Related]
9. Tolerability of rofecoxib versus naproxen. Jenkinson ML Ann Intern Med; 2004 Jun; 140(12):1059-60; author reply 1060. PubMed ID: 15197027 [No Abstract] [Full Text] [Related]
10. Recurrent aseptic meningitis due to different non-steroidal anti-inflammatory drugs including rofecoxib. Ashwath ML; Katner HP Postgrad Med J; 2003 May; 79(931):295-6. PubMed ID: 12782779 [TBL] [Abstract][Full Text] [Related]
12. Tolerability of rofecoxib versus naproxen. Hanauer LB Ann Intern Med; 2004 Jun; 140(12):1059; author reply 1060. PubMed ID: 15197026 [No Abstract] [Full Text] [Related]
13. Fixed drug eruption to rofecoxib. Nedorost ST; Florentino FT; Gilliam AC Cutis; 2002 Aug; 70(2):125-6. PubMed ID: 12234159 [TBL] [Abstract][Full Text] [Related]
14. Tolerability of rofecoxib. Asero R Allergy; 2001 Sep; 56(9):916-7. PubMed ID: 11551261 [No Abstract] [Full Text] [Related]
15. Lessons from the withdrawal of rofecoxib. Dieppe PA; Ebrahim S; Martin RM; Jüni P BMJ; 2004 Oct; 329(7471):867-8. PubMed ID: 15485938 [TBL] [Abstract][Full Text] [Related]
16. Is rofecoxib safer than naproxen? Adelman A J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204 [No Abstract] [Full Text] [Related]
17. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring data. Layton D; Heeley E; Hughes K; Shakir SA Rheumatology (Oxford); 2003 May; 42(5):622-31. PubMed ID: 12709537 [TBL] [Abstract][Full Text] [Related]
18. [Gynecomastia secondary to rofecoxib]. Martínez JA; Tejada González P; Gutiérrez Sanpedro N; González Blanco P Med Clin (Barc); 2002 Jun; 118(20):798-9. PubMed ID: 12049701 [No Abstract] [Full Text] [Related]
19. Adverse oral reactions associated with the COX-2 inhibitor rofecoxib. Bagán JV; Thongprasom K; Scully C Oral Dis; 2004 Nov; 10(6):401-3. PubMed ID: 15533219 [TBL] [Abstract][Full Text] [Related]